NeuroClues, developed by P3Lab, leverages advanced eye-tracking technology to offer a non-invasive method for detecting and monitoring neurological diseases long before symptoms appear. It provides clinicians with real-time, objective biomarkers that improve early diagnosis and track disease progression with high precision. It integrates these insights to support more accurate assessments and better patient management.
📋 Overview of neuroClues
Founding Year
2020
Estimated Funding
Size
$0000
Locations
Primary Industry
📙 About neuroClues
💰 Recent Investors of neuroClues
European Innovation Council Fund, Fiona Monceau, Investor
© 2025 Bot Memo. All Rights Reserved.
